KeViRx Receives Groundbreaking Grant Funding to Advance Revolutionary Small Molecule Technology


KeViRx, a cutting-edge pharmaceutical company, has recently been awarded a $1.99 million grant from the U.S. Department of Defense’s Peer Reviewed Medical Research Program. The funding will enable KeViRx to propel its groundbreaking small molecule platform technology, KVX-053, towards Investigational New Drug (IND) status.

Acute lung injury (ALI) affects a significant number of patients in the United States each year, resulting from various causes such as viral infection, sepsis, pneumonia, or exposure to toxins. The most severe form of ALI is known as acute respiratory distress syndrome (ARDS), from which 40% of patients sadly do not survive.

Addressing these limitations, KeViRx’s KVX-053 is a remarkable small molecule inhibitor of the PTP4A3 phosphatase. This innovative compound exhibits potent immunomodulatory and anti-inflammatory properties, allowing for the restoration of damaged endothelial barrier functions. By repairing the endothelial barrier in the vasculature, KVX-053 prevents tissue edema, migration of inflammatory cells, inflammation, and ultimately respiratory failure.

CEO Elizabeth R. Sharlow expresses her appreciation for the grant and recognizes its potential impact on patients’ lives. KeViRx intends for KVX-053 to revolutionize the treatment landscape for ALI/ARDS. Collaboration with esteemed researcher John Catravas, the Sentara Chair and Professor at Old Dominion University’s Frank Reidy Research Center for Bioelectrics, has been pivotal in advancing the technology.

It is important to note that this grant is supported by The Assistant Secretary of Defense for Health Affairs and the Department of Defense. The U.S. Army Medical Research Acquisition Activity is the administering acquisition office. For more details, visit KeViRx’s official website.

KeViRx, founded in 2016 and headquartered in Charlottesville, VA, is a privately held biotechnology company specializing in the development of small molecule drugs targeting microvascular leakage and inflammation. By focusing on the PTP4A3 phosphatase, a critical regulator of endothelial barrier function, KeViRx aims to make significant strides in the treatment of various diseases, including respiratory diseases like ALI.

The University of Virginia Licensing & Ventures Group plays a crucial role in KeViRx’s mission as it manages intellectual property and facilitates the commercialization of UVA discoveries. Additionally, Old Dominion University, a prominent institution located in Norfolk, Virginia, spearheads valuable research in various fields, boasting a top R1 research ranking.

KeViRx’s receipt of this grant funding underscores the company’s commitment to revolutionizing the pharmaceutical industry and providing innovative treatments for patients suffering from acute lung injury. With the support of esteemed partners and experts in the field, KeViRx is one step closer to changing the lives of countless individuals.

The article discusses KeViRx, a pharmaceutical company that has received a $1.99 million grant from the U.S. Department of Defense’s Peer Reviewed Medical Research Program. The funding aims to accelerate the development of their small molecule technology, KVX-053, towards Investigational New Drug (IND) status. This technology specifically targets acute lung injury (ALI), including the severe form known as acute respiratory distress syndrome (ARDS).

KeViRx’s KVX-053 is an innovative small molecule inhibitor of the PTP4A3 phosphatase, which plays a critical role in endothelial barrier function. By inhibiting this phosphatase, KVX-053 exhibits immunomodulatory and anti-inflammatory properties, leading to the restoration of damaged endothelial barrier functions. This prevents tissue edema, inflammatory cell migration, inflammation, and ultimately, respiratory failure.

One key advantage of KeViRx’s technology is its potential to significantly improve the treatment landscape for ALI/ARDS. By specifically targeting the underlying mechanisms of the condition and promoting endothelial barrier repair, KVX-053 offers a novel approach to addressing this life-threatening condition.

In terms of market trends, there is an increasing demand for innovative treatments for respiratory diseases like ALI/ARDS. The global acute respiratory distress syndrome (ARDS) therapeutics market is expected to witness significant growth in the coming years, driven by the rising prevalence of respiratory disorders and the need for effective interventions. Moreover, the ongoing COVID-19 pandemic has further highlighted the importance of developing therapies for respiratory conditions, making KeViRx’s focus on ALI/ARDS highly relevant.

Despite the promising potential of KeViRx’s technology, there are also several challenges and controversies associated with the development of small molecule drugs. One key challenge is the lengthy and rigorous process of obtaining regulatory approval, including the need to demonstrate safety and efficacy through extensive clinical trials. Additionally, there may be concerns about the cost and accessibility of these advanced treatments, as pharmaceutical innovation often comes with a high price tag.

In conclusion, KeViRx’s receipt of the grant funding marks a significant milestone in the advancement of their small molecule technology for ALI/ARDS treatment. The company’s collaboration with esteemed researchers and academic institutions further enhances its potential for success. However, it is important to recognize the challenges and controversies that accompany the development and commercialization of small molecule drugs.

For more information, please visit KeViRx’s official website: KeViRx.